Latest Health News

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

OM Holdings reported steady revenue of US$309.3 million in 1H 2025 despite a sharp EBITDA decline and net loss, while maintaining a strong cash position and advancing sustainability goals.

NRW Holdings has agreed to acquire Fredon Industries for up to $200 million, introducing a new strategic pillar and broadening its service capabilities in energy transition and infrastructure. The deal is expected to complete by September 30, 2025, with strong earnings visibility for FY26.

NRW Holdings has agreed to acquire Fredon Industries for up to $200 million, significantly broadening its electrical, mechanical, infrastructure, and technology services. The deal is expected to boost NRW’s earnings and open new growth avenues tied to energy transition and digital innovation.

Advanced Braking Technology (ABT) reported robust FY25 financial results marked by revenue growth and improved profitability, while advancing its strategic roadmap focused on mining safety innovations and global market expansion.

Race Oncology has activated its first clinical trial site in Hong Kong for the Phase 1 study of RC220 combined with doxorubicin in advanced solid tumours, marking a significant step in accelerating patient enrolment and broadening clinical data.

TALi Digital has successfully placed 446 million shares to close the shortfall from its recent entitlement offer, raising $446,000. The company also highlights its strategic acquisition of You Can Do It! Education, expanding its reach in digital health and social-emotional learning.

Biome Australia has partnered with Green Cross Health to launch its Activated Probiotics across New Zealand’s largest pharmacy network, marking a pivotal step in its international growth strategy.

Ryder Capital Limited reports a striking 12.75% preliminary gain in its investment portfolio for August 2025, lifting its pre-tax net tangible assets per share to $1.964 before dividend payout.

Pro Medicus’s U.S. subsidiary Visage Imaging has earned a critical Authority to Operate from the U.S. Department of Veterans’ Affairs, enabling its Visage 7 CloudPACS platform to transition to the Veterans Affairs Enterprise Cloud.

RLF AgTech has completed a $4.5 million placement by issuing over 90 million new shares, bolstering its capacity to advance sustainable crop nutrition solutions across Australia and Asia.

Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.